Mirati Therapeutics, Inc. (MRTX) News
Filter MRTX News Items
MRTX News Results
|Loading, please wait...|
MRTX News Highlights
- MRTX's 30 day story count now stands at 33.
- Over the past 27 days, the trend for MRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- The most mentioned tickers in articles about MRTX are DRUG, LUNG and USER.
Latest MRTX News From Around the Web
Below are the latest news stories about Mirati Therapeutics Inc that investors may wish to consider to help them evaluate MRTX as an investment opportunity.
Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report) today and set a price target of $165.00. The company's shares closed last Tuesday at $107.39, close to its 52-week low of $98.55. According to TipRanks.com, Roy is a 4-star analyst with an average return of 12.9% and a 32.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mirati Therapeutics with a $168.20 average price target, implying a 63.4% upside from current levels.
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!
A longer-than-expected regulatory review for the company''s lung cancer drug is weighing on its shares today.
(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks.
Mirati Therapeutics (MRTX) is trading ~7% lower in the pre-market on Wednesday. Read more about the reason
At least two Street firms have cut price targets on Mirati Therapeutics (MRTX) after the company Tuesday said its New Drug Application for its KRAS inhibitor. adagrasib will get a…